CervoMed Inc. (CRVO)
| Market Cap | 35.92M -53.3% |
| Revenue (ttm) | 4.01M -58.9% |
| Net Income | -26.97M |
| EPS | -2.98 |
| Shares Out | 9.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,410 |
| Open | 3.880 |
| Previous Close | 3.850 |
| Day's Range | 3.790 - 3.950 |
| 52-Week Range | 3.510 - 13.130 |
| Beta | -5.04 |
| Analysts | Strong Buy |
| Price Target | 23.00 (+492.78%) |
| Earnings Date | May 11, 2026 |
About CRVO
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38α. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant... [Read more]
Financial Performance
In 2025, CervoMed's revenue was $4.01 million, a decrease of -58.86% compared to the previous year's $9.74 million. Losses were -$26.97 million, 65.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for CRVO stock is "Strong Buy." The 12-month stock price target is $23.0, which is an increase of 492.78% from the latest price.
News
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial design
CervoMed Transcript: The 38th Annual Roth Conference
Significant progress was reported in developing a targeted therapy for DLB, with strong phase II results and a de-risked phase III trial set to launch by year-end. Biomarker-driven patient selection and updated manufacturing processes are expected to enhance efficacy and market potential.
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology
New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer's disease (AD) co-pathology — experienced greater clinical benefit wit...
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026 Obtained alignment with FDA and global regulators for planned Phase 3 trial design in...
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
Bioavailability data recently obtained from Phase 1 study with a stable crystal form of neflamapimod manufactured using a new, controlled manufacturing process Pharmacokinetic profile of the new, stab...
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targe...
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
1st of two presentations with results from Phase 2b study of neflamapimod at the 18 th Clinical Trials on Alzheimer's Disease (CTAD) Conference
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB
CervoMed Transcript: Emerging Growth Conference
Neflamapimod is advancing to phase 3 for pure DLB, targeting a large unmet need with strong phase 2 data showing significant clinical and biomarker improvements. The upcoming 24-week trial will enroll about 300 patients, with FDA feedback expected soon.
CervoMed to Present at the Emerging Growth Conference
BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today ...
CervoMed Drug Cut Dementia Progression Risk By 75% In Trial
CervoMed Inc. (NASDAQ:CRVO) on Wednesday shared additional data from its Phase 2b RewinD-LB trial of neflamapimod for dementia with Lewy bodies (DLB).
CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies
Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), demonstrated in a within-subject analysis in participants with low lik...
CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today ...
CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference
BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today...
CervoMed Transcript: H.C. Wainwright 27th Annual Global Investment Conference
A novel therapy for pure DLB patients showed significant clinical and biomarker improvements in phase 2 trials, with plans for a pivotal phase III study. The company expects FDA feedback in Q4 and will seek $50–75 million in funding for the next trial phase.
CervoMed to Participate in Upcoming Investor Conferences
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company ma...
CervoMed's Dementia Data Show Slowed Disease Progression
CervoMed Inc. CRVO on Monday shared 32-week data from the Extension phase of its Phase 2b RewinD-LB trial evaluating oral neflamapimod in patients with Dementia with Lewy Bodies (DLB).
CervoMed Transcript: Status Update
Sustained 32-week data from the phase IIb trial show neflamapimod significantly slows DLB progression and reduces neurodegeneration biomarkers, especially in patients without Alzheimer's co-pathology. Plans are underway for a phase III trial using the 40 mg TID dose and CDR-SB as the primary endpoint.
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at...
CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025
BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver ...
CervoMed Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025
Neflamapimod, an oral drug for DLB, showed significant clinical benefits in phase IIb trials, reducing disease progression by over 50% and supporting a strong case for a single pivotal phase III trial. The DLB market is large and underserved, with high pricing potential and flexible commercialization strategies.
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB)
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver...